This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum
See You Next Year! 26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Shobha Ravipaty, PhD
Director at Stoke Therapeutics


Shobha Ravipaty is a Director in the Translational DMPK & Clinical Pharmacology group at Stoke Therapeutics where she supports late discovery, pre-clinical and clinical development programs.

Prior to joining Stoke in 2019, Shobha worked at BPGbio (formerly Berg) where she led a team of scientists responsible for developing, qualifying/validating and implementing LC-MS or immunoassay based bioanalytical methods for quantitation of small molecule/protein therapeutics and biomarkers in a regulated environment (CLIA) to support non-clinical, clinical and diagnostic programs. Shobha started her career in the industry as a Scientist at Celerion focusing on regulated (GLP) bioanalysis. Shobha earned her PhD degree in Analytical Chemistry from Michigan Technological University and received postdoctoral training in mass spectrometry-based proteomics at Indiana University.

Agenda Sessions

  • Preclinical Data for STK-002, an Antisense Oligonucleotide Being Developed for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)